These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 15663328)

  • 41. Oncolytic viral therapies - the clinical experience.
    Aghi M; Martuza RL
    Oncogene; 2005 Nov; 24(52):7802-16. PubMed ID: 16299539
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A conditionally replicating adenovirus with strict selectivity in killing cells expressing epidermal growth factor receptor.
    Carette JE; Graat HC; Schagen FH; Mastenbroek DC; Rots MG; Haisma HJ; Groothuis GM; Schaap GR; Bras J; Kaspers GJ; Wuisman PI; Gerritsen WR; van Beusechem VW
    Virology; 2007 Apr; 361(1):56-67. PubMed ID: 17184803
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
    Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
    J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Extended release of adenovirus from silica implants in vitro and in vivo.
    Kangasniemi L; Koskinen M; Jokinen M; Toriseva M; Ala-Aho R; Kähäri VM; Jalonen H; Ylä-Herttuala S; Moilanen H; Stenman UH; Diaconu I; Kanerva A; Pesonen S; Hakkarainen T; Hemminki A
    Gene Ther; 2009 Jan; 16(1):103-10. PubMed ID: 18754041
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Reducing the immunostimulatory activity of CpG-containing plasmid DNA vectors for non-viral gene therapy.
    Yew NS; Cheng SH
    Expert Opin Drug Deliv; 2004 Nov; 1(1):115-25. PubMed ID: 16296724
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cancer selective adenoviruses.
    Alemany R
    Mol Aspects Med; 2007 Feb; 28(1):42-58. PubMed ID: 17300834
    [TBL] [Abstract][Full Text] [Related]  

  • 47. VSV-G pseudotyped, MuLV-based, semi-replication-competent retrovirus for cancer treatment.
    Qiao J; Moreno J; Sanchez-Perez L; Kottke T; Thompson J; Caruso M; Diaz RM; Vile R
    Gene Ther; 2006 Oct; 13(20):1457-70. PubMed ID: 16724095
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Targeting metastatic cancer from the inside: a new generation of targeted gene delivery vectors enables personalized cancer vaccination in situ.
    Gordon EM; Levy JP; Reed RA; Petchpud WN; Liu L; Wendler CB; Hall FL
    Int J Oncol; 2008 Oct; 33(4):665-75. PubMed ID: 18813779
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intra-peritoneal administration of genetic therapies: promises and pitfalls.
    Evans TR; Keith WN
    Minerva Ginecol; 2004 Dec; 56(6):529-38. PubMed ID: 15729205
    [TBL] [Abstract][Full Text] [Related]  

  • 50. A new recombinant vaccinia with targeted deletion of three viral genes: its safety and efficacy as an oncolytic virus.
    Yang S; Guo ZS; O'Malley ME; Yin X; Zeh HJ; Bartlett DL
    Gene Ther; 2007 Apr; 14(8):638-47. PubMed ID: 17268533
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Concurrent delivery of GM-CSF and B7-1 using an oncolytic adenovirus elicits potent antitumor effect.
    Choi KJ; Kim JH; Lee YS; Kim J; Suh BS; Kim H; Cho S; Sohn JH; Kim GE; Yun CO
    Gene Ther; 2006 Jul; 13(13):1010-20. PubMed ID: 16525479
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Naturally oncolytic viruses.
    Roberts MS; Lorence RM; Groene WS; Bamat MK
    Curr Opin Mol Ther; 2006 Aug; 8(4):314-21. PubMed ID: 16955694
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Le morte du tumour: histological features of tumor destruction in chemo-resistant cancers following intravenous infusions of pathotropic nanoparticles bearing therapeutic genes.
    Gordon EM; Chan MT; Geraldino N; Lopez FF; Cornelio GH; Lorenzo CC; Levy JP; Reed RA; Liu L; Hall FL
    Int J Oncol; 2007 Jun; 30(6):1297-307. PubMed ID: 17487349
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Taming the Trojan horse: optimizing dynamic carrier cell/oncolytic virus systems for cancer biotherapy.
    Power AT; Bell JC
    Gene Ther; 2008 May; 15(10):772-9. PubMed ID: 18369325
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Lentiviral vectors for cancer immunotherapy: transforming infectious particles into therapeutics.
    Breckpot K; Aerts JL; Thielemans K
    Gene Ther; 2007 Jun; 14(11):847-62. PubMed ID: 17361214
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The molecular perspective: restriction endonucleases.
    Goodsell DS
    Stem Cells; 2002; 20(2):190-1. PubMed ID: 11897876
    [No Abstract]   [Full Text] [Related]  

  • 57. Bioengineered microbes in disease therapy.
    Paton AW; Morona R; Paton JC
    Trends Mol Med; 2012 Jul; 18(7):417-25. PubMed ID: 22721939
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Standards for gene therapy clinical trials based on pro-active risk assessment in a London NHS Teaching Hospital Trust.
    Bamford KB; Wood S; Shaw RJ
    QJM; 2005 Feb; 98(2):75-86. PubMed ID: 15655100
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Does bacterial infection cause genome instability and cancer in the host cell?
    Kovalchuk O; Walz P; Kovalchuk I
    Mutat Res; 2014 Mar; 761():1-14. PubMed ID: 24472301
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of Bacteria in Cancer Therapy.
    Sarotra P; Medhi B
    Recent Results Cancer Res; 2016; 209():111-121. PubMed ID: 28101691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.